CFDE Data Portal | Search IBTK

	Label	Description
	IBTK associations Collection (Entity type)	Associations for IBTK_associations
	IBTK associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	IBTK Gene (Entity type)	ENSG00000005700 - inhibitor of Bruton tyrosine kinase
	GSE207871 NPC knockdown S18 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE120370 0 V 6 THROMBIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 FOXA1 inhibition prostate gland Ivermectin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146687 2 V 5 ERIBULIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

IBTK associations

Associations for IBTK_associations

IBTK associations.tsv

A file from IDG as part of the Harmonizome project

IBTK

ENSG00000005700 - inhibitor of Bruton tyrosine kinase

GSE207871 NPC knockdown S18 1 v 0 human up

A Gene Set from LINCS

GSE120370 0 V 6 THROMBIN MOUSE UP

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE UP

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

A Gene Set from LINCS

GSE169356 ivermectin prostate gland 0 v 1 human up

A Gene Set from LINCS

GSE169356 FOXA1 inhibition prostate gland Ivermectin 0 v 1 human up

A Gene Set from LINCS

GSE146687 2 V 5 ERIBULIN HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.